ElevateBio, LLC was conceived in 2018 as a central hub for both cell and gene therapy R&D and manufacturing that could meet the needs of many regenerative medicine start-ups all the way through commercialization, including ventures founded by the company. With $525m in series C venture capital round announced on 15 March, ElevateBio plans to expand its model to new locations that could support additional companies.
[Sidebar#SC125213]






